N/A
Completed N=32
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
Dyskinesias · Movement Disorders · Parkinson's Disease
Source: ClinicalTrials.gov NCT00467597 ↗
Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcomePrimary: Gaitmat Stance Measurements (AUC) — 4.48; 10.8; 20.9; 2.8 Root Mean Square of Velocity*Minutes
Summary
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gaitmat Stance Measurements (AUC) |
4.48; 10.8; 20.9; 2.8 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of probable idiopathic Parkinson's Disease or no neurologic disease (no disease for controls only)
- At least 21 years of age
- Mini Mental Status Exam Score>=25
Exclusion Criteria
- Evidence of psychosis (hallucinations or delusions) by history
- Any unstable medical condition
- Currently using dopamine blocking medication
- Currently taking anticoagulants or MAO inhibitors
Data sourced from ClinicalTrials.gov (NCT00467597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.